VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

David P. Carbone, J. Stuart Salmon, David D Billheimer, Heidi Chen, Alan Sandler, Heinrich Roder, Joanna Roder, Maxim Tsypin, Roy S. Herbst, Anne S. Tsao, Hai T. Tran, Thao P. Dang

Research output: Contribution to journalArticle

41 Scopus citations


We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat®) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat® could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.

Original languageEnglish (US)
Pages (from-to)337-340
Number of pages4
JournalLung Cancer
Issue number3
Publication statusPublished - Sep 2010
Externally publishedYes



  • Bevacizumab
  • Erlotinib
  • Lung cancer
  • Personalized therapy
  • Proteomics
  • Serum biomarker

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Medicine(all)

Cite this